NEW HAVEN, Conn., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (“Artizan”), a precision medicine biotechnology company, today announced the selection of its lead product candidate, ARZC-001, for the treatment of inflammatory bowel disease (“IBD”). Discovered internally and wholly owned by Artizan, ARZC-001 is a novel, oral, gut-restricted potent small molecule inhibitor that is designed to neutralize a specific secreted factor of microbial-driven dysregulation and inflammation in the intestine.
NEW HAVEN, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (“Artizan”), a biotechnology company at the frontier of microbiome precision medicine, and Biohaven Therapeutics Ltd. (“Biohaven”, parent company NYSE:BHVN), a commercial-stage Neuroinnovation company, today announced the companies are initiating a therapeutic discovery and development program in Parkinson’s disease (PD), to exploit recent scientific advances in the understanding of pathogenic roles played by the gut microbiome in PD. This follows the companies’ first collaboration announced in March 2021 centered on Artizan-discovered product candidates for the treatment of inflammatory bowel disease (IBD).